ViaNautis
Cambridge, GB · 44 employees on LinkedIn · 10 known investors
Find your way into ViaNautis
ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines. A UCL spin-out originally established as SomaServe in 2018, the company operates from facilities in Cambridge, UK.
Founders & leadership
DA
Dr Adi Hoess
DR
Dr Ray Jupp
DS
Dr Samuel Barker
DS
Dr Sarah Wythe
SS
Sam Smart
Investors · 10
Cambridge Angels groupCambridge · $195K – $1.9M
Oxford Investment Opportunity Network (OION)Oxford · $190K – $2.5M
4BIO CapitalreportedLondon
Origin CapitalreportedSingapore
UCB VenturesreportedBrussels
Also in the syndicate · 5
BGFleadCystic Fibrosis FoundationEli Lilly and CompanyMeltwindO2H
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AOct 2024
4BIO Capital (lead), BGF (lead), UCB Ventures (lead), Cystic Fibrosis Foundation, Eli Lilly and Company, Meltwind, O2H, Origin Capital
Source ↗ - Undisclosed amountSeries ANov 2023
4BIO Capital (lead), BGF (lead), UCB Ventures (lead), Cystic Fibrosis Foundation, Eli Lilly and Company, Meltwind, O2H, Origin Capital
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does ViaNautis do?
- ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines. A UCL spin-out originally established as SomaServe in 2018, the company operates from facilities in Cambridge, UK.
- Who are ViaNautis's investors?
- ViaNautis's investors include Cambridge Angels group, Oxford Investment Opportunity Network (OION), 4BIO Capital, Origin Capital, UCB Ventures.
- Where is ViaNautis headquartered?
- ViaNautis is headquartered in Cambridge, GB.